Validation Data Gallery
Tested Applications
| Positive IF-P detected in | mouse colon tissue |
Recommended dilution
| Application | Dilution |
|---|---|
| Immunofluorescence (IF)-P | IF-P : 1:50-1:500 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
CL488-16233 targets VIP in IF-P applications and shows reactivity with human, mouse, rat samples.
| Tested Reactivity | human, mouse, rat |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen | VIP fusion protein Ag8933 相同性解析による交差性が予測される生物種 |
| Full Name | vasoactive intestinal peptide |
| Calculated molecular weight | 169 aa, 19 kDa |
| GenBank accession number | BC009794 |
| Gene Symbol | VIP |
| Gene ID (NCBI) | 7432 |
| RRID | AB_3083986 |
| Conjugate | CoraLite® Plus 488 Fluorescent Dye |
| Excitation/Emission maxima wavelengths | 493 nm / 522 nm |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | P01282 |
| Storage Buffer | PBS with 50% Glycerol, 0.05% Proclin300, 0.5% BSA, pH 7.3. |
| Storage Conditions | Store at -20°C. Avoid exposure to light. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
Vasoactive intestinal peptide (VIP), a short peptide containing 28 amino acids belonging to the secretin-glucagon family, is initially isolated from the gastrointestinal tract as a potent vasodilator peptide. VIP was initially identified in normal nervous tissue and neurons and was subsequently recognized as a neurotransmitter widely distributed in various tissues. The wide distribution of VIP determines its involvement in a range of biological activities, such as gut motility, hormonal regulation, circadian rhythms, immune responses, and carcinogenesis. The general physiologic effects of VIP include vasodilation, anti-inflammatory actions, cell proliferation, hormonal secretion, regulation of gastric motility, and smooth muscle relaxation; therefore, VIP has emerged as a promising drug candidate for the treatment of several diseases.
Protocols
| Product Specific Protocols | |
|---|---|
| IF protocol for CL Plus 488 VIP antibody CL488-16233 | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |